Somatrogon

Indication

Treating growth disturbance in children and young people aged 3 years and over (NICE TA863)

NICE TA863 - Somatrogon for treating growth disturbance in children and young people aged 3 years and over

Red

Brand:

Ngenla

Nice TA:

863

Commissioning responsibility:

CCG

PbR excluded:

Yes

BNF chapter:

Endocrine system

Background

1.1 Somatrogon is recommended, within its marketing authorisation, as an option for treating growth disturbance caused by growth hormone deficiency in children and young people aged 3 years and over.

Recommendation

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

Decisions of Lancashire local decision making groups

BwD	BP	CSR	EL	FW	GP	MB	WL
Red	Red	Red	Red	Red	Red	Red	Red

What do the colours mean?

Last Updated: 17 - Mar - 2023

Breadcrumb

Somatrogon

Indication

Background

Recommendation

Decisions of Lancashire local decision making groups